Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,038.06 +19.67 (+0.39%) Dow
38,055.87 +152.58 (+0.40%) Nasdaq
15,731.49 +126.01 (+0.81%) Bitcoin USD
58,988.33 +1,882.54 (+3.30%) CMC Crypto 200
1,274.41 +3.66 (+0.29%)
Alzamend Neuro, Inc. (ALZN)
- Insider Monkey
Insiders Are Buying These 11 Penny Stocks
In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock market started the second quarter of 2024 in the red, driven by rising treasury yields, broader volatility and uncertainty around rate cuts […]
- Benzinga
EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year
Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD). "Although lithium does not have an FDA-approved indication for PTSD, it has been prescribed off-label for this purpose for decades," said Stephan Jackman, Chief Executive Officer of Alzamend. "If we can develop a next-generation lithium product (AL001) that would not routinely require therapeutic drug m
- Business Wire
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
ATLANTA, December 11, 2023--Alzamend Neuro Receives FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug to Treat PTSD
